Login to Your Account

Regulatory NEWS

While it's far from dead on arrival, the proposed 21st Century Cures Act that seeks to streamline the development and approval of new drugs and devices in the U.S. could be waylaid by the clamor over escalating drug prices.

HONG KONG – In an effort to encourage innovation and upgrade China's pharmaceutical sector, China's drug watchdog continues to target companies with weak clinical trial data.

More drug companies are getting swept into the congressional onslaught against large price increases, with little attention paid to the reason for the hike.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: